Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

lab%20tests.jpeg

Patients Believe Lab Tests More Than Doctors

Patients believe that a lab result is a numeric true representation their biology and a pivotal arbiter of wellness, yet physicians often dismiss such results as hanging chads in a meaningless election. Why do patients believe their labs moreso than their doctor? 

Read Article
lab.blood-315278__340.jpg

ANA Negative Lupus Nephritis - Does it Exist?

A recent report from the Mayo Clinic describes a 49 year-old patient with lupus nephritis who presented with new-onset hypertension, edema, arthritis, serositis and leukocytoclastic vasculitis, and who later developed glomerulonephritis and nephrotic syndrome.

Read Article
ultrasound2.jpg

Ultrasound Predicts Inflammatory Arthritis in CCP+ Persons Without Synovitis

A prospective study of 136 people who were CCP+, but who had no clinical evidence of synovitis, examined what factors may predict future development of inflammatory arthritis.

Read Article
downward_0.jpg

NIH-Funded Trials Down, While Industry Trials Increase

(Reuters Health) – Every year since 2006 in the U.S., the amount of new medical research in humans funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. 

Read Article
t22t.jpg

Updated RA Treat-to-Target International Recommendations

In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).

Read Article
CNS.demyelinating.jpg

Risk of Multiple Sclerosis with TNF Inhibitor Therapy

Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi). 

Read Article
biosimilars2.jpg

Biosimilar Reports - January 2016

Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.

Read Article
analysis.jpg

UK Audit Shows Early RA Referrals Still Too Slow

A national audit of rheumatoid arthritis (RA) and early inflammatory arthritis patients included 6,354 patients drawn from 143 trusts and health boards in England and Wales. Early arthritis clinics exist in 57% of trusts.

Read Article
50958362_s.jpg

PML is Very Rare in Lupus

A systematic review of the literature was done to assess the relationship between immunosuppressive therapy, adult systemic lupus erythematosus (SLE) and the onset of progressive multifocal leukoencephalopathy.

Read Article
OP.density.jpg

ASBMR Guidance on Bisphosphonate Use

The American Society of Bone and Mineral Research (ASBMR) Task Force has issued a guidance report on the use of bisphosphonates (BP) with a focus on the risk vs. benefits of such therapy. (Citation source http://buff.ly/1Nn0CVb)

Read Article
×